Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
412.10 | 67,160 Cr | 135.59 | 1.95 | 0.12 | 1.14 | 3.64 | 0.65 | ||
2326.00 | 65,645 Cr | 36.51 | 6.24 | 0.21 | 28.08 | 32.70 | 9.03 | ||
5380.00 | 64,326 Cr | 29.82 | 4.65 | 0.99 | 16.66 | 18.61 | 10.57 | ||
26933.65 | 57,234 Cr | 35.45 | 11.99 | 2.44 | 32.51 | 42.54 | 24.83 | ||
2900.40 | 47,979 Cr | 42.50 | 4.63 | 0.69 | 9.92 | 14.02 | 9.02 | ||
1883.40 | 47,783 Cr | 36.48 | 5.93 | 0.32 | 14.15 | 18.58 | 11.15 | ||
3725.00 | 46,399 Cr | 40.88 | 10.25 | 0.76 | 23.33 | 29.09 | 18.44 | ||
| Median: 7 Co. | — | 2900.40 | 57,234 Cr | 36.51 | 5.93 | 0.69 | 16.66 | 18.61 | 10.57 |
Biocon is a fully integrated, innovation‑led biopharmaceutical company from India focused on biosimilars, complex biologics, interchangeable insulins, generic formulations, peptides (GLP‑1s) and research/CRDMO services through Syngene with global manufacturing and commercialization reach across North America, Europe and emerging markets.
The group is at an operational inflection: major capex is largely complete, operating leverage is beginning to play out, and management highlights margin expansion and cash‑flow led value creation as priorities while retaining significant R&D investment of about INR 249 crore in Q3 FY26.
Biocon’s biosimilars franchise is accelerating commercial traction with multiple regulatory wins (MHRA, EMA approvals) and launches; the company lists roughly 17 oncology assets and cites an approximately US$75+ billion addressable opportunity in oncology and immunology, reflecting deliberate pipeline focus.
Financially, Q3 FY26 showed resilience: consolidated operating revenue of INR 4,173 crore (up 9% YoY), core EBITDA growth of 21% YoY to INR 1,221 crore, biosimilars EBITDA up 44% YoY, and a reported net profit recovery driven by favorable mix, higher‑margin prioritization and balance sheet simplification.
Pharmaceuticals & Biotechnology
Pharmaceuticals
67,160 Cr
Low Risk
135.6
36.9
1.6
2.0
447.00
337.20
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Biocon Ltd (BIOCON) is currently trading at 418.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Biocon is a fully integrated, innovation‑led biopharmaceutical company from India focused on biosimilars, complex biologics, interchangeable insulins, generic formulations, peptides (GLP‑1s) and research/CRDMO services through Syngene with global manufacturing and commercialization reach across North America, Europe and emerging markets. The group is at an operational inflection: major capex is largely complete, operating leverage is beginning to play out, and management highlights margin expansion and cash‑flow led value creation as priorities while retaining significant R&D investment of about INR 249 crore in Q3 FY26. Biocon’s biosimilars franchise is accelerating commercial traction with multiple regulatory wins (MHRA, EMA approvals) and launches; the company lists roughly 17 oncology assets and cites an approximately US$75+ billion addressable opportunity in oncology and immunology, reflecting deliberate pipeline focus. Financially, Q3 FY26 showed resilience: consolidated operating revenue of INR 4,173 crore (up 9% YoY), core EBITDA growth of 21% YoY to INR 1,221 crore, biosimilars EBITDA up 44% YoY, and a reported net profit recovery driven by favorable mix, higher‑margin prioritization and balance sheet simplification.
Over the past 52 weeks, Biocon Ltd has traded between a low of ₹337.20 and a high of ₹447.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Biocon Ltd has a market capitalization of approximately 67,159.70. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Biocon Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 135.59 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 67,159.70 Cr, Biocon Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Biocon Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Biocon Ltd is 135.59. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Revenue from operations was ₹4,336 crore in Q1 FY27, up 10.00% year-on-year from ₹3,942 crore.
It announced a new settlement and licence agreement with Regeneron and Bayer covering Europe and the rest of the world, enabling worldwide commercialisation of Yesafili.
Yesafili is aflibercept-jbvf, a VEGF inhibitor and biosimilar to Eylea. It is associated with Biocon Biologics, a subsidiary of Biocon Ltd.
Reports said the deal removed a large supply overhang, with Mylan selling its entire 5.64% stake in one transaction, which improved near-term sentiment.
Bearish
3
Neutral
6
Bullish
5
Bearish
21
Neutral
6
Bullish
19
Bearish
18
Neutral
0
Bullish
14
Bearish
3
Neutral
6
Bullish
5
Bearish
3
Neutral
6
Bullish
5
Bearish
18
Neutral
0
Bullish
14
Bearish
18
Neutral
0
Bullish
14
Bearish
18
Neutral
0
Bullish
14
